SHARE

Amicus Therapeutics, Inc. (NASDAQ:FOLD) witnessed a sharp increase in its volume after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed the company’s migalastat for Fabry disease.

Fabry disease

The Committee found the drug appropriate as a first-line therapy for patients with the amenable genetic mutation. However, the European Commission (EC) will take the final call only during the second quarter of 2016. Approval from the EC will take forward Amicus to start reimbursement processes country-by-country.

The CHMP has approved the label for the drug for nearly 269 mutations stemmed from Fabry. Such approval represents nearly 50% of the patients impacted by Fabry disease. On receiving the positive opinion from the CHMP, Amicus’ Chairman and CEO, John F. Crowley, said that the Committee’s opinion serves as a considerable milestone for both the Fabry disease-impacted patients and the company.

269 mutations referred

He went on to state that the label approved by the CHMP is broad and reflects nearly 35% to 50% of the Fabry community. Thus, it represents a significant opportunity for the company to address the treatment needs of a wide Fabry cases. The company expressed its gratitude towards Fabry patients, who chose to participate in the clinical studies of migalastat.

Following the receipt of the positive opinion from the CHMP, the company is set to spearhead its launch related activities across countries in Europe. Meanwhile, Prof. Dominique P. Germain, MD, Ph.D., Division of Medical Genetics at the University of Versailles and Assistance Publique, regards the positive opinion as a successful event for the company and places it on the track to gain EC’s nod.

The Committee has recommended the use of the drug in adults and adolescents aged 16 years and more. The stock of Amicus gained 2.84% to $8.69 during the previous day’s trading session.

SHARE
Previous articleGilead Sciences, Inc. (NASDAQ:GILD) Submits NDA For TAF In Japan
Next articleAmgen, Inc. (NASDAQ:AMGN) Surges On Repatha’s Effectiveness In Clinical Trials
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.

LEAVE A REPLY